Jefferies Downgrades Fusion Pharmaceuticals to Hold, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Andrew Tsai downgraded Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold but increased the price target from $10 to $21.

March 19, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Fusion Pharmaceuticals was downgraded by Jefferies from Buy to Hold, although the price target was raised from $10 to $21.
The downgrade from Buy to Hold suggests a neutral outlook on the stock's immediate growth potential, indicating that the stock might not outperform the market in the short term. However, the significant increase in the price target from $10 to $21 reflects a positive long-term view on the company's value. This mixed signal could lead to short-term price volatility as investors adjust to the new valuation and outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100